Latest & greatest articles for insulin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on insulin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on insulin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for insulin

981. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. (Abstract)

Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lipodystrophy is a major side-effect of antiretroviral therapy but its pathophysiology remains elusive. In-vitro studies show that HIV-1-protease inhibitors affect adipocyte differentiation at an early step involving sterol-regulatory-element-binding-protein-1 (SREBP1), but in-vivo studies are lacking.We (...) of SREBP1c and downstream adipogenic factors. SREBP1c mRNA concentrations correlated negatively, and TNFalpha mRNA concentrations positively, with glycaemia and insulin resistance, but did not correlate with lipid variables.The altered differentiation status of peripheral adipocytes in HIV-1-infected patients with antiretroviral-induced lipoatrophy is associated with greatly reduced SREBP1c expression. Since the differentiation factor SREBP1 is rapidly targeted by protease inhibitors in vitro, our

2002 Lancet

982. Association between genetic variation in the gene for insulin-like growth factor-I and low birthweight. (Abstract)

Association between genetic variation in the gene for insulin-like growth factor-I and low birthweight. Low birthweight is associated with later risk of type 2 diabetes and related disorders. We aimed to show that a polymorphism in the gene for insulin-like growth factor-I, which has proved to raise risk of type 2 diabetes and myocardial infarction, is associated with low birthweight. We recorded birthweight and obtained DNA for 463 adults. Individuals who did not have the wild-type allele

2002 Lancet

983. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. (Abstract)

Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. Increased levels of asymmetric dimethylarginine (ADMA) are associated with endothelial dysfunction and increased risk of cardiovascular disease. Several cardiovascular risk factors are associated with reduced sensitivity to insulin, but elevated ADMA concentrations have not been fully linked to the metabolic syndrome.To evaluate the relationship between insulin sensitivity and plasma ADMA concentrations (...) , and to determine whether a pharmacological treatment that increases insulin sensitivity would also modulate ADMA concentrations.Cross-sectional study, containing a nonrandomized controlled trial component, of 64 healthy volunteers without diabetes (42 women, 22 men; 48 with normal blood pressure and 16 with hypertension), which was conducted at a university medical center between October 2000 and July 2001.Rosiglitazone (4 mg/d for 4 weeks and then 4 mg twice daily for 8 weeks), an insulin-sensitizing agent

2002 JAMA

984. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. (Abstract)

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Glucagon-like peptide 1 (GLP-1) has been proposed as a treatment for type 2 diabetes. We have investigated the long-term effects of continuous administration of this peptide hormone in a 6-week pilot study.20 patients with type 2 diabetes were alternately assigned continuous subcutaneous infusion of GLP-1 (n=10) or saline (n=10) for 6 (...) weeks. Before (week 0) and at weeks 1 and 6, they underwent beta-cell function tests (hyperglycaemic clamps), 8 h profiles of plasma glucose, insulin, C-peptide, glucagon, and free fatty acids, and appetite and side-effect ratings on 100 mm visual analogue scales; at weeks 0 and 6 they also underwent dexascanning, measurement of insulin sensitivity (hyperinsulinaemic euglycaemic clamps), haemoglobin A(1c), and fructosamine. The primary endpoints were haemoglobin A(1c) concentration, 8-h profile

2002 Lancet

985. Guidance on the use of long-acting insulin analogues for the treatment of diabetes û insulin glargine (TA53)

Guidance on the use of long-acting insulin analogues for the treatment of diabetes û insulin glargine (TA53) Guidance on the use of long‑acting insulin analogues for the treatment of diabetes – insulin glargine | Guidance | NICE Guidance on the use of long‑acting insulin analogues for the treatment of diabetes – insulin glargine Technology appraisal guidance [TA53] Published date: 06 December 2002 Last updated: 01 August 2015 Guidance This guidance has been replaced by . Explore © NICE [year

2002 National Institute for Health and Clinical Excellence - Technology Appraisals

986. Protocol for outpatient screening and initiation of continuous subcutaneous insulin infusion therapy: impact on cost and quality

Protocol for outpatient screening and initiation of continuous subcutaneous insulin infusion therapy: impact on cost and quality Protocol for outpatient screening and initiation of continuous subcutaneous insulin infusion therapy: impact on cost and quality Protocol for outpatient screening and initiation of continuous subcutaneous insulin infusion therapy: impact on cost and quality Sanfield J A, Hegstad M, Hanna R S Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of an outpatient screening protocol to identify patients with Type I diabetes who would be suited for continuous subcutaneous insulin infusion (CSII), and who would continue the treatment for two and a half years. Type of intervention Screening

2002 NHS Economic Evaluation Database.

987. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials

Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients (...) with type 1 diabetes: meta-analysis of randomised controlled trials Pickup J, Mattock M, Kerry S Authors' objectives To compare glycaemic control and insulin dosage in people with type 1 diabetes who are treated by continuous subcutaneous insulin infusion (insulin infusion pump therapy) or optimised insulin injections. Searching Published trials that met the inclusion criteria were identified by searching MEDLINE (from 1975 to 2000) and EMBASE (from 1980 to 2000) for literature on insulin infusion

2002 DARE.

988. Glucose and insulin responses to dietary chromium supplements: a meta-analysis

Glucose and insulin responses to dietary chromium supplements: a meta-analysis Glucose and insulin responses to dietary chromium supplements: a meta-analysis Glucose and insulin responses to dietary chromium supplements: a meta-analysis Althuis M D, Jordan N E, Ludington E A, Wittes J T Authors' objectives To evaluate the effect of dietary chromium supplements on glucose and insulin response in healthy people and in people with glucose intolerance or type 2 diabetes. Searching The Cochrane (...) in nondiabetic patients was around 5 mmol/L. The primary studies included elderly, overweight people, athletes, participants in exercise or dietary interventions, people with mild forms of diabetes, people with atherosclerosis, and older African American women. Outcomes assessed in the review The inclusion criteria were not explicitly defined in terms of the outcomes. The outcomes assessed in the review were glucose and insulin concentration and glycated haemoglobin (HbA1c). Glucose and insulin concentration

2002 DARE.

989. Insulin pumps, conventional and intensive multiple injection insulin therapy for type 1 diabetes mellitus

Insulin pumps, conventional and intensive multiple injection insulin therapy for type 1 diabetes mellitus Insulin pumps, conventional and intensive multiple injection insulin therapy for type 1 diabetes mellitus Insulin pumps, conventional and intensive multiple injection insulin therapy for type 1 diabetes mellitus Oduneye F Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation Oduneye F. Insulin pumps, conventional and intensive multiple injection insulin therapy for type 1 diabetes mellitus. London: Bazian Ltd (Editors), Wessex Institute for Health Research and Development, University of Southampton 2002: 8 Authors' objectives This study aims to assess the effects of continuous insulin infusion pumps compared with multiple injection and conventional insulin therapy in people with type 1 diabetes mellitus. Authors' conclusions We found good evidence

2002 Health Technology Assessment (HTA) Database.

990. Guidance on the use of long-acting insulin analogues for the treatment of diabetes insulin glargine

Guidance on the use of long-acting insulin analogues for the treatment of diabetes insulin glargine Guidance on the use of long-acting insulin analogues for the treatment of diabetes insulin glargine Guidance on the use of long-acting insulin analogues for the treatment of diabetes insulin glargine National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation National Institute for Clinical Excellence. Guidance on the use of long-acting insulin analogues for the treatment of diabetes insulin glargine. London: National Institute for Clinical Excellence (NICE). Technology Appraisal Guidance 53. 2002 Authors' objectives To provide guidance on the use of long-acting insulin analogues for the treatment of diabetes insulin glargine. Authors' conclusions Guidance: 1.1 Insulin glargine is recommended as a treatment option for people

2002 Health Technology Assessment (HTA) Database.

991. Are there time and cost savings by using telemanagement for patients on intensified insulin therapy: a randomised, controlled trial

Are there time and cost savings by using telemanagement for patients on intensified insulin therapy: a randomised, controlled trial Are there time and cost savings by using telemanagement for patients on intensified insulin therapy: a randomised, controlled trial Are there time and cost savings by using telemanagement for patients on intensified insulin therapy: a randomised, controlled trial Biermann E, Dietrich W, Rihl J, Standl E Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Telemanagement was compared with conventional outpatient management for patients on intensified insulin therapy. Telemanagement procedures permit the transfer of self-monitored blood glucose values, stored together with date and time in memory

2002 NHS Economic Evaluation Database.

992. Effects of insulin in relatives of patients with type 1 diabetes mellitus. Full Text available with Trip Pro

Effects of insulin in relatives of patients with type 1 diabetes mellitus. It is unknown whether insulin therapy can delay or prevent diabetes in nondiabetic relatives of patients with diabetes.In a randomized, controlled, nonblinded clinical trial, we screened 84,228 first-degree and second-degree relatives of patients with diabetes for islet-cell antibodies; 3152 tested positive; 2103 of the 3152 underwent genetic, immunologic, and metabolic staging to quantify their risk; 372 of the 2103 had (...) a projected five-year risk of more than 50 percent; 339 of the 372 (median age, 11.2 years) were randomly assigned to undergo either close observation or an intervention that consisted of low-dose subcutaneous ultralente insulin, administered twice daily for a total dose of 0.25 unit per kilogram of body weight per day, plus annual four-day continuous intravenous infusions of insulin. Oral glucose-tolerance tests were performed every six months. Median follow-up was 3.7 years. The primary end point

2002 NEJM Controlled trial quality: uncertain

993. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. Full Text available with Trip Pro

Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. To compare glycaemic control and insulin dosage in people with type 1 diabetes treated by continuous subcutaneous insulin infusion (insulin infusion pump therapy) or optimised insulin injections.Meta-analysis of 12 randomised controlled trials.301 people with type 1 diabetes allocated to insulin infusion (...) and 299 allocated to insulin injections for between 2.5 and 24 months.Glycaemic control measured by mean blood glucose concentration and percentage of glycated haemoglobin. Total daily insulin dose.Mean blood glucose concentration was lower in people receiving continuous subcutaneous insulin infusion compared with those receiving insulin injections (standardised mean difference 0.56, 95% confidence interval 0.35 to 0.77), equivalent to a difference of 1.0 mmol/l. The percentage of glycated haemoglobin

2002 BMJ

994. Effects of moderate alcohol intake on fasting insulin and glucose concentrations and insulin sensitivity in postmenopausal women: a randomized controlled trial. (Abstract)

Effects of moderate alcohol intake on fasting insulin and glucose concentrations and insulin sensitivity in postmenopausal women: a randomized controlled trial. Epidemiologic data demonstrate that moderate alcohol intake is associated with improved insulin sensitivity in nondiabetic individuals. No controlled-diet studies have addressed the effects of daily moderate alcohol consumption on fasting insulin and glucose concentrations and insulin sensitivity.To determine whether daily consumption (...) of low to moderate amounts of alcohol influences fasting insulin and glucose concentrations and insulin sensitivity in nondiabetic postmenopausal women.Randomized controlled crossover trial of 63 healthy postmenopausal women, conducted at a clinical research center in Maryland between 1998 and 1999.Participants were randomly assigned to consume 0, 15, or 30 g/d of alcohol for 8 weeks each as part of a controlled diet. All foods and beverages were provided during the intervention. An isocaloric

2002 JAMA Controlled trial quality: uncertain

995. Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial. Full Text available with Trip Pro

Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial. To evaluate whether a course teaching flexible intensive insulin treatment combining dietary freedom and insulin adjustment can improve both glycaemic control and quality of life in type 1 diabetes.Randomised design with participants either attending training immediately (immediate DAFNE) or acting as waiting list (...) control in people with type 1 diabetes without worsening severe hypoglycaemia or cardiovascular risk. This approach has the potential to enable more people to adopt intensive insulin treatment and is worthy of further investigation.

2002 BMJ Controlled trial quality: uncertain

996. Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: a randomized controlled trial. (Abstract)

Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: a randomized controlled trial. Limited information exists on the interaction between diet and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) and the interaction's effect on serum lipid and lipoprotein levels, insulin sensitivity, and circulating antioxidant vitamin and provitamin levels.To evaluate the separate and combined effects of diet and simvastatin therapy (...) ; triglycerides; apolipoprotein B; insulin; glucose; and antioxidants at week 12 of each treatment period, compared among the 4 groups.Dietary treatment decreased levels of total cholesterol by 7.6% (P<.001), LDL cholesterol by 10.8% (P<.001), HDL cholesterol by 4.9% (P =.01), apolipoprotein B by 5.7% (P =.003), serum insulin by 14.0% (P =.02), and alpha-tocopherol by 3.5% (P =.04). Simvastatin decreased levels of total cholesterol by 20.8%, LDL cholesterol by 29.7%, triglycerides by 13.6%, apolipoprotein B

2002 JAMA Controlled trial quality: predicted high

997. Insulins today and beyond. (Abstract)

Insulins today and beyond. The advent of insulin almost 80 years ago revolutionised treatment of diabetes and must be one of the most outstanding achievements of twentieth century medicine. Since then, there has been an ever-increasing awareness and acceptance of the need to achieve and sustain near-normoglycaemia to delay onset and retard progression of diabetic angiopathy. Physiological insulin replacement is therefore central to management of patients with diabetes who are unable to make (...) [corrected] insulin. Insulin formulations, treatment strategies, and methods and routes of delivery have changed much, with more and more options for monitoring the effect on blood glucose concentrations. Patients with type 1 and type 2 diabetes need insulin much more aggressively than previously. Parallel developments in glucose-sensing technologies are welcomed as an integral part of safe and optimum implementation of insulin replacement therapy.

2001 Lancet

998. Insulin therapy in patients with type 2 diabetes mellitus: shared care versus secondary outpatient care in The Netherlands

Insulin therapy in patients with type 2 diabetes mellitus: shared care versus secondary outpatient care in The Netherlands Insulin therapy in patients with type 2 diabetes mellitus: shared care versus secondary outpatient care in The Netherlands Insulin therapy in patients with type 2 diabetes mellitus: shared care versus secondary outpatient care in The Netherlands Hutubessy R C, Vondeling H, de Sonnaville J J, Colly L P, Smit J L, Heine R J Record Status This is a critical abstract (...) for the management of patients with Type 2 diabetes initiating insulin therapy. The service consisted of a patient registration and recall system plus a laboratory. A dietician and a specific diabetes educator provided diabetes education. A supervising diabetologist could be consulted by telephone 24 hours a day. The patients were monitored at least at 3-month intervals and feedback was provided to the GP. Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study

2001 NHS Economic Evaluation Database.

999. Intensive insulin therapy in critically ill patients. (Abstract)

Intensive insulin therapy in critically ill patients. Hyperglycemia and insulin resistance are common in critically ill patients, even if they have not previously had diabetes. Whether the normalization of blood glucose levels with insulin therapy improves the prognosis for such patients is not known.We performed a prospective, randomized, controlled study involving adults admitted to our surgical intensive care unit who were receiving mechanical ventilation. On admission, patients were (...) randomly assigned to receive intensive insulin therapy (maintenance of blood glucose at a level between 80 and 110 mg per deciliter [4.4 and 6.1 mmol per liter]) or conventional treatment (infusion of insulin only if the blood glucose level exceeded 215 mg per deciliter [11.9 mmol per liter] and maintenance of glucose at a level between 180 and 200 mg per deciliter [10.0 and 11.1 mmol per liter]).At 12 months, with a total of 1548 patients enrolled, intensive insulin therapy reduced mortality during

2001 NEJM Controlled trial quality: uncertain

1000. Inhaled insulin for the treatment of diabetes mellitus

Inhaled insulin for the treatment of diabetes mellitus Inhaled insulin for the treatment of diabetes mellitus Inhaled insulin for the treatment of diabetes mellitus McAuley L Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation McAuley L. Inhaled insulin for the treatment of diabetes mellitus. Ottawa: Canadian Coordinating Office for Health (...) Technology Assessment/Office Canadien de Coordination de l'Evaluation des Technologies de la Sante (CCOHTA) 2001: 4 Authors' objectives To summarise the available evidence on the use of inhaled insulin for the treatment of diabetes mellitus. Authors' conclusions - Insulin delivery via inhalation, as an alternative to administration by injection, is under development. - The available evidence comparing subcutaneous (sc) insulin with inhaled insulin for persons with type 1 and 2 diabetes, shows similar

2001 Health Technology Assessment (HTA) Database.